CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Mallinckrodt PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Mallinckrodt PLC
College Business & Technology Park
Cruiserath, Blanchardstown
Phone: +353 16960000p:+353 16960000 DUBLIN, Ireland Ticker: MCKPFMCKPF
Emerged from Bankruptcy on 11/14/2023
On 11/14/2023, Mallinckrodt plc announced that it has completed its financial restructuring, emerged from Chapter 11 and completed the Irish Examinership Proceedings.
Business Summary
Mallinckrodt plc develops, manufactures, markets, and distributes branded and generic specialty pharmaceutical products and therapies. The Company operates in two reportable segments: Specialty Brands and Specialty Generics. The Specialty Brands includes specialty pharmaceutical brands. The Specialty Generics includes niche specialty generic drugs and active pharmaceutical ingredients. Its Specialty Generics segment is focused on providing its customers with specialty generic drugs and active pharmaceutical ingredients (APIs). The Company focuses on various therapeutic areas, such as autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics, cultured skin substitutes and gastrointestinal products. Its product portfolio includes Acthar Gel, INOmax, Therakos photopheresis, StrataGraft, Terlivaz, and Amitiza.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes-Yes-

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/29/202312/29/2023YesYesYes-Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Paul M.Bisaro 62 6/16/2022 6/16/2022
President, Chief Executive Officer, Director SigurdurOlafsson 55 6/25/2022 6/25/2022
Chief Financial Officer, Executive Vice President Bryan M.Reasons 55 3/18/2019 3/18/2019
11 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Mallinckrodt Canada Coperatie U.A. Prins Bernhardplein 200 AMSTERDAM Netherlands
Mallinckrodt Netherlands B.V. Prins Bernhardplein 200 AMSTERDAM Netherlands
Mallinckrodt Petten Holdings B.V. Prins Bernhardplein 200 AMSTERDAM Netherlands
75 additional Subsidiary records available in full report.

Business Names
Business Name
Acthar IP Unlimited Company
Cache Holdings Limited
Cadence Pharmaceuticals, Inc.
108 additional Business Names available in full report.

General Information
Number of Employees: 2,800 (As of 12/29/2023)
Outstanding Shares: 19,696,335 (As of 3/22/2024)
Shareholders: 446
Stock Exchange: OTC
Federal Tax Id: 981088325


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, April 29, 2024